EUCTR2011-001303-13-DE进行中（未招募）不适用
HIV postexposure prophylaxis with Darunavir/r (PEPDar) - PEPDar
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Potential subjects must satisfy all of the following criteria to be enrolled in the study:
- •Man or woman greater than 18 years of age.
- •Occupational injury or non ocupational injury with documented HIV exposure, or potential for HIV exposure.
- •Indication for HIV PEP, as determined by the treating physician and/or the investigator.
- •If standard of care HIV PEP was initiated prior to screening, this should have occurred no more than 72 hours after injury and no more than 36 hours before screening.
- •If standard of care HIV PEP is to be initiated after screening, this should occur no more than 72 hours after injury.
- •Women must be:
- •postmenopausal (for at least 2 years),
- •surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
- •abstinent (at the discretion of the investigator/per local regulations), or
- •if sexually active, be practicing a highly effective method of birth control assuring a Pearl-Index below 1 (before entry, and must agree to continue to use the same method of contraception throughout the study. Women using oral contraceptives must agree to use an additional birth control method.
- •Women of childbearing potential must have a negative urine pregnancy test at screening.
- •Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug.
- •Willing to continue HIV PEP for at least 28 days and maximum of 30 days.
- •Willing/able to adhere to the prohibitions and restrictions specified in this protocol.
- •Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 318
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- •Positive HIV rapid test.
- •History of liver or renal insufficiency; significant cardiac, vascular, pulmonary, GI, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances.
- •Results of the serum chemistry panel, hematology, or urinalysis measurements at screening (which may only be available after screening) are outside the normal reference ranges, and the investigator judges the abnormalities or deviations from normal to be clinically significant or not appropriate and reasonable for the population under study. This determination must be recorded in the subject’s source documents and initialed by the investigator.
- •Note: Because this study is conducted in an emergency setting, some or all of the laboratory results may not be available at the time of randomization, but subjects can still be enrolled and randomized in the absence of this information. Laboratory results that become available after randomization must be checked immediately after receipt and if this exclusion criterion is then met, subjects must be withdrawn from the study afterwards.
- •Contraindication for any component of the DRV/r PEP or standard of care PEP.
- •Known allergies, hypersensitivity, or intolerance to the active pharmaceutical ingredients or any excipients (refer to Section 14.1, Physical Description of Study Drug[s]) of the DRV/r PEP or standard of care PEP, or to sulfonamides.
- •Received an investigational drug (including vaccines) or used an investigational medical device within 1 month before the start of treatment or are currently enrolled in an investigational study.
- •Pregnant or breast-feeding.
- •Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements.
研究者
相似试验
已完成
3 期
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)Human Immunodeficiency Virus (HIV)NCT01516970Janssen-Cilag G.m.b.H312
尚未招募
2 期
Post-Exposure Prophylaxis with Favipiravir among Household Close Contacts to Confirmed COVID-19 cases: Cluster-Randomized TrialHousehold contacts with SARS-CoV-2 index caseFavipiravir, post-exposure prophylaxis, household, Favipiravir solution, COVID-19, SARS-CoV-2TCTR20210909002Chulabhorn Royal Academy156
终止
4 期
Implementation of Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis with antiretroviral medications amongst men at high risk for HIV infection; a demonstration projectHIV preventionInfection - Acquired immune deficiency syndrome (AIDS / HIV)Public Health - Other public healthACTRN12615000032550Cairns and Hinterland Hospital and Health Service3,000
进行中（未招募）
1 期
periconceptional preventive therapy with anti-HIV drugs in women with a partner infected with HIVEUCTR2014-003874-17-ITational Institute for Infectious Diseases Lazzaro Spallanzani IRCCS30
尚未招募
不适用
Evaluating the role of mobile Health platform and peer to peer mentoring in improving adherence to HIv pre-exposure prophylaxis among high risk population in TanzaniaHIV/AIDSPACTR202003823226570niversity of Oslo2,500